Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01161498|
Recruitment Status : Terminated (The changing aetiology of squamous cell carcinoma of the head and neck (SCCHN).)
First Posted : July 13, 2010
Results First Posted : December 17, 2015
Last Update Posted : February 8, 2016
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Squamous Cell Carcinoma Head and Neck Cancer||Biological: Talimogene Laherparepvec Radiation: Radiation Drug: Cisplatin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||5 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 3 Randomized Trial of Concurrent Cisplatin & Radiotherapy With Or Without ONCOVEX^GM-CSF In Previously Untreated Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck|
|Study Start Date :||February 2011|
|Actual Primary Completion Date :||October 2011|
|Actual Study Completion Date :||October 2011|
Active Comparator: Radiation/Cisplatin
Participants received cisplatin (100 mg/m²) administered intravenously on Days 0, 21, and 42. Radiation was administered concurrently with cisplatin in 35 fractions over a 7-week period.
70 grays of radiation administered in 35 fractions over 7 weeks
Administered by intravenous infusion
Experimental: Talimogene Laherparepvec + Radiation/Cisplatin
The first dose of talimogene laherparepvec was up to 8 mL total volume (up to 4 mL per lesion) at 10⁶ plaque-forming units (PFU)/mL, administered into all injectable affected nodes on Day 0. Subsequent doses were up to 8 mL total volume (up to 4 mL per lesion) at 10⁸ PFU/mL on Days 21, 42, and 63. Participants also received cisplatin (100 mg/m²) administered intravenously on Days 0, 21, and 42 and radiation administered concurrently in 35 fractions over a 7-week period.
Biological: Talimogene Laherparepvec
Administered by intratumoral injection
70 grays of radiation administered in 35 fractions over 7 weeks
Administered by intravenous infusion
- 2-year Event-free Survival [ Time Frame: 2 years ]Event-free survival is defined as the time from randomization until the first evidence of relapse, disease progression (local, regional, metastatic, or second primary), or death from any cause. Because this study was terminated with only 5 participants enrolled, and the study was terminated in the first year, this endpoint was not analyzed.
- Clinical Objective Response (cOR) [ Time Frame: End of trial; the maximum time on study was 20 weeks. ]
Tumor response was assessed by computed tomography (CT) scan according to a modified version of the revised Response Evaluation Criteria In Solid Tumors (RECIST) criteria (version 1.1). Objective response is defined as achieving a clinical partial response (cPR) or complete response (cCR). cCR is defined as disappearance of all baseline lesions. Any pathological lymph nodes must have a reduction in short axis to < 10 mm. cPR is defined as at least a 30% decrease in the sum of diameters of baseline lesions. Progressive disease (PD) is defined as at least a 20% increase in the sum of diameters of baseline lesions, taking as reference the smallest sum on study, and an absolute increase of at least 5 mm, or the appearance of any new lesions.
Because this study was terminated with 5 patients enrolled, data for this endpoint were summarized in by-patient listings only and the cOR rate was not calculated. Therefore a summary of response at the end of study is reported.
- Metabolic Complete Response (mCR) [ Time Frame: End of study; the maximum time on study was 20 weeks. ]
Response to therapy was assessed using [(18)F] fluorodeoxyglucose positron emission tomography (FDG PET) imaging to detect metabolically active tumors.
Metabolic complete response (mCR) is defined as complete disappearance of FDG uptake attributable to tumor compared to baseline scan.
Partial metabolic response (mPR) is defined as a > 40% decrease in specific uptake compared to the initial value in over half of the lesions.
Disease progression (mPD) is defined as a specific uptake increase in any lesion, appearance of new lesions, or presence of extended areas of disease activity.
Stable metabolic response (mSD) is defined as a decrease in uptake < 40% of the initial value of over half the lesions.
Because this study was terminated with 5 patients enrolled, data for this endpoint were summarized in by-patient listings only and the metabolic complete response rate was not calculated. Therefore a summary of metabolic response at end of study is reported.
- Pathologic Complete Response (mCR) [ Time Frame: Up to Week 20 ]
Response to therapy was assessed histopathologically from biopsies taken at surgery for those participants who had surgery prior to Week 22.
If no viable tumor cells were identified in surgical specimens (where the patient had surgery) the patient was classified as having a pathological complete response (pCR), and if viable tumor cells were identified, the patient was classified as having an incomplete pathologic response.
Because this study was terminated with 5 patients enrolled, data for this endpoint were summarized in by-patient listings only and the pathologic complete response rate was not calculated. Therefore a summary of participants with a pathologic complete response before the end of study is reported.
- Time to Locoregional Failure [ Time Frame: Up to 27 months ]
Locoregional failure is defined as disease progression in the head and neck area at any time following completion of chemoradiotherapy.
Because this study was terminated with 5 subjects enrolled, time to locoregional failure was not analyzed.
- Time to Distant Failure [ Time Frame: Up to 27 months ]
Distant failure is defined as disease progression at any site other than the head and neck area at any time following completion of chemoradiotherapy.
Because this study was terminated with 5 participants enrolled, time to distant failure was not analyzed.
- Time to Any Failure [ Time Frame: Up to 27 months ]
Any failure is defined as disease progression at any site at any time following completion of chemoradiotherapy.
Because this study was terminated with 5 participants enrolled, time to any failure was not analyzed.
- Overall Survival [ Time Frame: Up to 5 years after chemoradiotherapy ]
Overall survival is defined as the time from randomization to death from any cause.
Because this study was terminated with 5 participants enrolled, overall survival was not analyzed.
- Disease-specific Survival [ Time Frame: Up to 5 years after chemoradiotherapy ]
Disease-specific survival is defined as the time from randomization to death of the patient due to the cancer under study.
Because this study was terminated with 5 participants enrolled, disease-specific survival was not analyzed.
- Participants With N1-2 Disease at Baseline Requiring Neck Dissection [ Time Frame: Weeks 19 - 21 ]Participants with Baseline Nl or N2 disease (lymph node metastasis not more than 6 cm in greatest dimension) with persistent disease as determined at the post chemoradiotherapy assessment of response were to proceed to neck dissection as permitted by the institution no later than Week 22. Since this study terminated prematurely neck dissection data were not collected or analyzed.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Male or female ≥ 18 years
- Eastern Co-Operative Oncology Group (ECOG) Performance Status ≤ 1
- Histological evidence (from the primary lesion and/or lymph nodes) of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx
- Stage III or IV disease (T2N2-3M0, T3-4N1-3M0)
- No evidence of distant metastases by computed tomography (CT) or positron emission tomography (PET)/CT scan
- Life expectancy > 4 months
- Neutrophil count ≥ 2,000/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin ≥ 10 g/dL
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times ULN
- Alkaline phosphatase ≤ 2.5 times ULN
- Creatinine clearance ≥ 60 mL/min
- Female patients of child-bearing potential (i.e. not surgically sterile, or not having spontaneous amenorrhea for at least 12 months) must agree to use an effective form of contraception during the treatment phase of the study.
- Male patients must agree to use a condom with spermicide or their female partner must use an effective method of birth control.
- Provide written informed consent in accordance with all applicable regulations and follow the study procedures. Patients must be capable of understanding the investigational nature, potential risks and benefits of the study.
- Prior treatment for locally advanced SCCHN (No prior surgery for SCCHN except nodal sampling or biopsy for study disease).
- Patients with T1-2N1 or T1N2-3.
- Pre-existing peripheral neuropathy ≥ Grade 2 (motor or sensory).
- Weight loss > 20% of body weight within 3 months of screening (unless purposeful).
- Surgery ≤ 28 days before randomization with the exception of feeding tube placement, dental extractions, central venous catheter placement, biopsies and nodal sampling.
- Cancer of the nasopharynx, sinus, salivary gland or skin.
- Previous radical radiation therapy (RT) to the head and neck region, excluding superficial RT for a non-melanomatous skin cancer.
- Prior cancers, except: those diagnosed > 5 years ago with no evidence of disease recurrence and clinical expectation of recurrence of less than 5%; or successfully treated non-melanoma skin cancer; or carcinoma in situ of the cervix.
- Significant intercurrent illness that will interfere with the chemotherapy or radiation therapy such as human immunodeficiency (HIV) infection, cardiac failure, pulmonary compromise (chronic obstructive pulmonary disease, pneumonia or respiratory decompensation) resulting in hospitalization within 12 months of screening, or active infection.
- Any significant cardiac disease (e.g., New York Heart Association (NYHA) Class 3 or 4; myocardial infarction within the past 6 months; unstable angina; coronary angioplasty or coronary artery bypass graft (CABG) within the past 6 months; or uncontrolled atrial or ventricular cardiac arrhythmias..
- High risk for poor compliance with therapy or follow up as assessed by the investigator.
- Active herpes labialis, other lesions due to herpes simplex virus type I (HSV1) or dermatoses involving or within 50 cm of the lesions to be injected; active HSV1 lesions must have resolved before talimogene laherparepvec is injected.
- Prior systemic chemotherapy for any type of cancer.
- Patients for whom radiation therapy is contraindicated.
- Pregnant or breast-feeding female. Confirmation that women of child-bearing potential are not pregnant. A negative serum β- human chorionic gonadotropin (β-hCG) pregnancy test result must be obtained during the screening period.
- Currently enrolled and receiving an investigational agent in a clinical research study or received an investigational agent for any reason within 4 weeks prior to screening.
- Require intermittent or chronic treatment with an anti-herpetic drug (e.g., acyclovir), other than intermittent topical use.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01161498
|United States, Indiana|
|Investigative Clinical Research of Indiana|
|Indianapolis, Indiana, United States, 46260|
|United States, Kentucky|
|James Graham Brown Cancer Center, University of Louisville|
|Louisville, Kentucky, United States, 40202|
|United States, Ohio|
|Gabrail Cancer Center|
|Canton, Ohio, United States, 44718|
|United States, South Carolina|
|Medical Univesity of South Carolina|
|Charleston, South Carolina, United States, 29425|
|United States, Virginia|
|VCU Massey Cancer Center|
|Richmond, Virginia, United States, 23298|
|The Royal Marsden Hospital|
|London, United Kingdom, SE1 7EH|
|Principal Investigator:||Kevin Harrington, MD||Royal Marsden, UK|
|Responsible Party:||BioVex Limited|
|Other Study ID Numbers:||
20110130 ( Other Identifier: Amgen Inc. )
|First Posted:||July 13, 2010 Key Record Dates|
|Results First Posted:||December 17, 2015|
|Last Update Posted:||February 8, 2016|
|Last Verified:||January 2016|
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Neoplasms by Site
Antineoplastic Agents, Immunological